title: Time to initiation of antifungal therapy for neonatal candidiasis.
abstract: The effect of delayed antifungal therapy in critically ill infants with invasive candidiasis has not been studied. Our objective was to evaluate the effect of time to initiation of antifungal therapy (TIA) on mortality, disseminated disease, and postinfection hospital stay. We conducted a cohort study of critically ill infants with cultures positive for Candida from 1990 to 2008. TIA was defined as the number of hours from the collection of the first positive culture until the start of antifungal therapy. Of 96 infants, 57% were male, the median gestational age was 27 weeks (range, 23 to 41 weeks), and the median birth weight was 956 g (range, 415 to 6,191 g). Most subjects received amphotericin B deoxycholate. TIA was ≤ 24 h for 35% of infants, between 25 and 48 h for 42%, and >48 h for 23%. Eleven subjects died during hospitalization, and 22% had disseminated candidiasis. The median duration of hospital stay postinfection was 53 days (range, 6 to 217 days). Both univariate and multivariate analyses demonstrated that TIA was not associated with mortality, disseminated disease, or hospital stay postinfection. However, ventilator use for >60 days significantly increased the risk of death (odds ratio [OR], 9.5; 95% confidence interval [CI], 2.2 to 66.7; P = 0.002). Prolonged candidemia increased the risk of disseminated disease by 10% per day of positive culture (OR, 1.1; 95% CI, 1.08 to 1.2; P = 0.007), and low gestational age was associated with increased neonatal intensive care unit (NICU) stay after the first positive Candida culture by 0.94 weeks (95% CI, 0.70 to 0.98; P < 0.001). The TIA was not associated with all-cause mortality, disseminated candidiasis, and postinfection length of hospital stay.
authors.affiliation: University of California at San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA. jenle@ucsd.edu
authors.forename: Jennifer
authors.initials: J
authors.lastname: Le
authors.forename: Tu T
authors.initials: TT
authors.lastname: Tran
authors.forename: Ivilynn
authors.initials: I
authors.lastname: Bui
authors.forename: Mike K
authors.initials: MK
authors.lastname: Wang
authors.forename: Andrew
authors.initials: A
authors.lastname: Vo
authors.forename: Felice C
authors.initials: FC
authors.lastname: Adler-Shohet
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002175:Candida / Q000145:classification / Q000302:isolation & purification; D058365:Candidiasis, Invasive / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality* / Q000503:physiopathology; D015331:Cohort Studies; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality* / Q000503:physiopathology; D007363:Intensive Care Units, Neonatal; D007902:Length of Stay; D008297:Male; D013997:Time Factors; D061665:Time-to-Treatment; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B